HCA Healthcare Inc (HCA) Shares Sold by Reilly Financial Advisors LLC

Reilly Financial Advisors LLC trimmed its stake in HCA Healthcare Inc (NYSE:HCA) by 14.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,664 shares of the company’s stock after selling 2,751 shares during the period. Reilly Financial Advisors LLC’s holdings in HCA Healthcare were worth $2,318,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of HCA. WINTON GROUP Ltd boosted its stake in HCA Healthcare by 39.6% in the first quarter. WINTON GROUP Ltd now owns 6,954 shares of the company’s stock worth $675,000 after buying an additional 1,973 shares in the last quarter. Summit Trail Advisors LLC boosted its stake in HCA Healthcare by 9,933.3% in the first quarter. Summit Trail Advisors LLC now owns 112,774 shares of the company’s stock worth $113,000 after buying an additional 111,650 shares in the last quarter. Howard Capital Management Inc. boosted its stake in HCA Healthcare by 25.7% in the first quarter. Howard Capital Management Inc. now owns 3,282 shares of the company’s stock worth $319,000 after buying an additional 670 shares in the last quarter. Suntrust Banks Inc. boosted its stake in HCA Healthcare by 365.6% in the first quarter. Suntrust Banks Inc. now owns 23,513 shares of the company’s stock worth $2,279,000 after buying an additional 18,463 shares in the last quarter. Finally, Nicola Wealth Management LTD. purchased a new stake in HCA Healthcare in the first quarter worth approximately $2,910,000. Institutional investors own 70.44% of the company’s stock.

HCA stock traded down $1.38 on Friday, reaching $134.99. The company’s stock had a trading volume of 32,510 shares, compared to its average volume of 1,775,873. HCA Healthcare Inc has a 12-month low of $74.26 and a 12-month high of $141.11. The firm has a market capitalization of $47.22 billion, a price-to-earnings ratio of 20.76, a PEG ratio of 1.21 and a beta of 0.50. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of -7.64.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Wednesday, July 25th. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.13. HCA Healthcare had a negative return on equity of 61.68% and a net margin of 6.21%. The company had revenue of $11.53 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the firm posted $1.73 earnings per share. The firm’s revenue was up 7.4% on a year-over-year basis. Equities research analysts anticipate that HCA Healthcare Inc will post 9.23 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 28th. Investors of record on Tuesday, September 4th were paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date of this dividend was Friday, August 31st. HCA Healthcare’s payout ratio is 21.24%.

A number of analysts have recently weighed in on the company. ValuEngine lowered HCA Healthcare from a “buy” rating to a “hold” rating in a research note on Thursday, June 28th. SunTrust Banks increased their price objective on HCA Healthcare to $145.00 and gave the company a “buy” rating in a research note on Thursday, July 26th. Citigroup increased their price objective on HCA Healthcare from $136.00 to $156.00 and gave the company a “buy” rating in a research note on Thursday, October 11th. Barclays assumed coverage on HCA Healthcare in a research note on Tuesday, August 14th. They set an “overweight” rating and a $150.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $115.00 price objective on shares of HCA Healthcare in a research note on Friday, July 20th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $135.19.

In other HCA Healthcare news, SVP Jane D. Englebright sold 6,543 shares of the stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $129.86, for a total value of $849,673.98. Following the completion of the transaction, the senior vice president now owns 7,443 shares in the company, valued at $966,547.98. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Charles J. Hall sold 34,125 shares of the stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $129.93, for a total value of $4,433,861.25. Following the completion of the transaction, the insider now owns 98,124 shares of the company’s stock, valued at approximately $12,749,251.32. The disclosure for this sale can be found here. Insiders sold 170,257 shares of company stock valued at $21,118,053 in the last ninety days. 2.80% of the stock is currently owned by insiders.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

Read More: Beta

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare Inc (NYSE:HCA).

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply